In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer ...

19 analysts have expressed a variety of opinions on AbbVie ABBV over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ...

AbbVie ABBV underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings by ...